The effect of Xuefu Zhuyu decoction on clopidogrel resistance and its association with the P2Y12 Gene polymorphisms and promoter DNA methylation

被引:3
|
作者
Yu, Qinglin [1 ]
Su, Jia [2 ]
Zhu, Keqi [1 ]
Yang, Shujun [3 ]
Zhu, Hao [4 ]
Yu, Jingbo [2 ]
机构
[1] Ningbo 1 Hosp, Dept Tradit Chinese Internal Med, Ningbo, Zhejiang, Peoples R China
[2] Ningbo 1 Hosp, Dept Gerontol, Ningbo, Zhejiang, Peoples R China
[3] Ningbo 1 Hosp, Dept Hematol, Ningbo, Zhejiang, Peoples R China
[4] Ningbo 1 Hosp, Dept Anaesthesia, Ningbo, Zhejiang, Peoples R China
关键词
Xuefu Zhuyu decoction; clopidogrel resistance; P2Y12; polymorphisms; promoter DNA methylation; PERCUTANEOUS CORONARY INTERVENTION; TREATMENT PLATELET REACTIVITY; ANTIPLATELET THERAPY; MYOCARDIAL-INFARCTION; CARDIOVASCULAR EVENTS; BLOOD-CIRCULATION; PRASUGREL; DETERMINANTS; METAANALYSIS; EXPRESSION;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Some patients experience lesser degrees of platelet inhibition, which is known as clopidogrel resistance (CR). The goal of our study was to investigate the effects of Xuefu Zhuyu decoction on CR in coronary artery disease patients and whether P2Y12 polymorphisms and its methylation were related to drug response or not. 49 patients diagnosed with CR were randomly divided into control and treatment groups. Platelet functions were measured using Verify-Now P2Y12 assay. By restriction fragment length polymorphism-polymerase chain reaction, the single-nucleotide polymorphisms of rs2046934 and rs6785930 were genotyped. Using bisulphite pyrosequencing assay, we investigated the association of the P2Y12 gene DNA methylation levels and the effects of Xuefu Zhuyu decoction on CR. The results showed that the decoction improved CR (P= 0.005), and the patients with the TT genotype in rs2046934 received substantial benefits from Xuefu Zhuyu Decoction, in both P2Y12 reaction units (PRU) and inhibition percentage (P-PRU= 0.016; P-inhibition percentage = 0.028). And patients with lower methylation levels of CpG1 were more likely to be TT carriers in rs2046934 (CpG1(TT) Vs. CpG1(TC+CC)(%): 39.47 +/- 6.20 vs.45.70 +/- 8.47, P=0.044). In conclusion, our study indicated that Xuefu Zhuyu decoction might be useful for overcoming CR and the polymorphism of rs2046934 might influence the drug effect.
引用
收藏
页码:2565 / 2572
页数:8
相关论文
共 36 条
  • [1] Association of P2Y12 Gene Promoter DNA Methylation with the Risk of Clopidogrel Resistance in Coronary Artery Disease Patients
    Su, Jia
    Li, Xiaojing
    Yu, Qinglin
    Liu, Yahui
    Wang, Yaqing
    Song, Haojun
    Cui, Hanbin
    Du, Weiping
    Fei, Xiaohong
    Liu, Junsong
    Lin, Shaoyi
    Wang, Jian
    Zheng, Wenyuan
    Zhong, Jinyan
    Zhang, Lulu
    Tong, Maoqing
    Xu, Jin
    Chen, Xiaomin
    BIOMED RESEARCH INTERNATIONAL, 2014, 2014
  • [2] Association of PON1 gene promoter DNA methylation with the risk of Clopidogrel resistance in patients with coronary artery disease
    Su, Jia
    Li, Jiyi
    Yu, Qinglin
    Xu, Xiaofeng
    Wang, Jingqiao
    Yang, Jin
    Li, Xiaojing
    Chen, Xiaomin
    JOURNAL OF CLINICAL LABORATORY ANALYSIS, 2019, 33 (05)
  • [3] Clopidogrel resistance in North Indian patients of coronary artery disease and lack of its association with platelet ADP receptors P2Y1 and P2Y12 gene polymorphisms
    Kar, Rakhee
    Meena, Arvind
    Yadav, Birendra K.
    Yadav, Rakesh
    Kar, Sitanshu Sekhar
    Saxena, Renu
    PLATELETS, 2013, 24 (04) : 297 - 302
  • [4] The influence of P2Y12 gene polymorphisms on clopidogrel therapy in patients after percutaneous coronary intervention
    Pawlak, Kornel
    Danielak, Dorota
    Burchardt, Pawel
    Kruszyna, Lukasz
    Karazniewicz-Lada, Marta
    FUTURE CARDIOLOGY, 2024, 20 (7-8) : 377 - 387
  • [5] Effectiveness of Clopidogrel vs Alternative P2Y12 Inhibitors Based on the ABCD-GENE Score
    Thomas, Cameron D.
    Franchi, Francesco
    Rossi, Joseph S.
    Keeley, Ellen C.
    Anderson, R. David
    Beitelshees, Amber L.
    Duarte, Julio D.
    Ortega-Paz, Luis
    Gong, Yan
    Kerensky, Richard A.
    Kulick, Natasha
    Mcdonough, Caitrin W.
    Nguyen, Anh B.
    Wang, Yehua
    Winget, Marshall
    Yang, William E.
    Johnson, Julie A.
    Winterstein, Almut G.
    Stouffer, George A.
    Angiolillo, Dominick J.
    Lee, Craig R.
    Cavallari, Larisa H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (15) : 1370 - 1381
  • [6] P2RY12 Gene Polymorphisms and Effect of Clopidogrel on Platelet Aggregation
    Galic, Edvard
    Vrbanic, Luka
    Kapitanovic, Sanja
    Ivkovic, Tina Catela
    Petro, Dubravka
    Vukovic, Ivica
    Bsharat, Rebhi Sari
    Milicevic, Zvonko
    Vcev, Aleksandar
    Mirat, Jure
    COLLEGIUM ANTROPOLOGICUM, 2013, 37 (02) : 491 - 498
  • [7] The impact of P2Y12 promoter DNA methylation on the recurrence of ischemic events in Chinese patients with ischemic cerebrovascular disease
    Li, Xin-Gang
    Ma, Ning
    Wang, Bo
    Li, Xiao-Qing
    Mei, Sheng-Hui
    Zhao, Kun
    Wang, Yong-Jun
    Li, Wei
    Zhao, Zhi-Gang
    Sun, Shu-Sen
    Miao, Zhong-Rong
    SCIENTIFIC REPORTS, 2016, 6
  • [8] Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study
    Collet, Jean-Philippe
    Hulot, Jean-Sebastien
    Abtan, Jeremie
    Anzaha, Ghalia
    Kerneis, Mathieu
    Silvain, Johanne
    Cayla, Guillaume
    O'Connor, Stephen A.
    Barthelemy, Olivier
    Beygui, Farzin
    Galier, Sophie
    Brugier, Delphine
    Stanek, Eric J.
    Charland, Scott L.
    Gallois, Vanessa
    Montalescot, Gilles
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 70 (09) : 1049 - 1057
  • [9] Association between P2Y1 and P2Y12 polymorphisms and acute myocardial infarction and ADP-induced platelet aggregation
    Su, Chunyan
    Zhang, Zhishan
    Chen, Jintu
    Tian, Mengcha
    Wu, Conglian
    Zhang, Tao
    BMC CARDIOVASCULAR DISORDERS, 2023, 23 (01)
  • [10] P2Y12 Polymorphisms and the Risk of Adverse Clinical Events in Patients Treated with Clopidogrel: A Meta-Analysis
    Zhao, Kun
    Yang, Ming
    Lu, Yanxia
    Suns, Shusen
    Lib, Wei
    Li, Xingang
    Zhao, Zhigang
    DRUG RESEARCH, 2019, 69 (01) : 23 - 31